| Identification | Back Directory | [Name]
RRX-001 | [CAS]
925206-65-1 | [Synonyms]
RRX-001
[14C]-Rrx-001
RRX 001;RRX001
2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
Ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-
2-bromo-1-(3,3-dinitroazetidin-1-yl)ethan-1-one | [Molecular Formula]
C5H6BrN3O5 | [MDL Number]
MFCD25976849 | [MOL File]
925206-65-1.mol | [Molecular Weight]
268.02 |
| Chemical Properties | Back Directory | [Boiling point ]
473.0±45.0 °C(Predicted) | [density ]
1.98±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 2 mg/ml | [form ]
A solid | [pka]
-2.07±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
RRx-001 is a novel epigenetic modulator with potential radiosensitizing activity. In human tumor cells, it inhibits glucose 6-phosphate dehydrogenase (G6PD), binds to hemoglobin and drives RBC-mediated redox reactions under hypoxia.It can trigger apoptosis and has antitumor activity. | [in vitro]
RRx-001 exerts its antiproliferative effect by interfering with glucose 6 phosphate dehydrogenase (G6PD), a key enzyme in the pentose phosphate pathway. RRx-001 induces p53 and PARP-1 through ROS/RNS generation. It exerts its anticancer activity by interfering and disrupting 3 crucial metabolic demands in rapidly proliferating cells: bioenergetics, macromolecular biosynthesis and manipulation of cellular cytoplasmic redox homeostasis.RRx-001 also mediates the nuclear translocation of Nrf2 and the expression of its downstream HO-1 and NQO1 in tumor cells. | [in vivo]
RRx-001 has a short-term blood flow redistribution effect in tumors enriched in pericytes and α-SMA vessels.It was well tolerated without dose-limiting toxic side effects. In mice, it not only promoted nuclear transport of Nrf2, but also upregulated the expression of endogenous Nrf2 in SCC VII tumors. | [target]
| Target | Value | G6PD
() | | Nrf2-ARE |
|
|
|